Nivolumab Versus Docetaxel in Previously Treated Patients With Advanced Non-Small-Cell Lung Cancer: Two-Year Outcomes From Two Randomized, Open-Label, Phase III Trials (CheckMate 017 and CheckMate 057).

Nivolumab Versus Docetaxel in Previously Treated Patients With Advanced Non-Small-Cell Lung Cancer: Two-Year Outcomes From Two Randomized, Open-Label, Phase III Trials (CheckMate 017 and CheckMate 057). J Clin Oncol. 2017 Dec 10; 35(35):3924-3933.

View in: PubMed

subject areas

Antibodies, Monoclonal
Antineoplastic Agents
Carcinoma, Non-Small-Cell Lung
Humans
Kaplan-Meier Estimate
Lung Neoplasms
Survival Rate
Taxoids
Treatment Outcome

authors with profiles

Everett E. Vokes